While GLP-1 RA prevalence among non-diabetic adults held steady at 0.1% from 2018-2021, it quadrupled to 0.4% in 2022 alone
It showed a significant reduction in the incidence of CV death, nonfatal MI or nonfatal stroke in non-diabetic and overweight or obese and patients treated with Semaglutide 2.4 mg compared to placebo as a secondary prevention strategy for patients with cardiovascular diseases I encourage you all to explore the SELECT trial to gain a more comprehensive understanding of these findings
Ozempic may cause fatigue in some individuals, particularly during the initial stages of treatment as the body adjusts, but this side effect is typically temporary and often resolves over time
In the real world, participants receiving semaglutide had a similar number of days drinking as those receiving placebo, but they drank less on those days and had fewer heavy drinking days
Access to treatments in jeopardy Even as Marquez spoke of the prospect of widely available treatments, the board was finalizing plans to pass regulations that will severely restrict Californians access to sterile compounded substances, including glutathione
Concurrently, other studies are revealing more about GLP-1 receptor agonists effects on ocular conditions
.jpg&maxx=500&maxy=0)
